Tesamorelin
Growth Hormone-Releasing Hormone (1-44) amide
Tesamorelin is an FDA-approved synthetic growth hormone-releasing hormone (GHRH) analog specifically indicated for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. It works by stimulating the pituitary gland to release growth hormone, leading to targeted reduction in visceral adipose tissue through enhanced lipolysis and fat metabolism.
Complete Dosing Guide
Quick Reference
Administration Method
Daily subcutaneous injection in abdominal area on empty stomach
Step-by-Step Dosing Protocol
Dosing Guidelines
Standard dose is 2mg daily subcutaneous injection, administered consistently in the evening on an empty stomach. Dose should be taken 30 minutes before eating or 2 hours after eating. Treatment duration typically 6+ months for optimal visceral fat reduction. No dose escalation required - consistent 2mg daily from initiation.
Everyone takes the same dose of Tesamorelin - 2mg once a day as a shot. You take it in the evening on an empty stomach (either 30 minutes before eating or 2 hours after eating). Unlike some medications, you don't need to start low and increase - you take 2mg from day one and continue for at least 6 months.
Mixing & Injection
Subcutaneous injection in abdominal area using provided syringes after reconstituting lyophilized powder with diluent. Rotate injection sites within abdominal region to prevent lipodystrophy. Reconstitute immediately before use - do not store mixed solution. Administer consistently at same time each evening for optimal growth hormone rhythm.
Subcutaneous injection in abdominal area using provided syringes after reconstituting lyophilized powder with diluent. Rotate injection sites within abdominal region to prevent lipodystrophy. Reconstitute immediately before use - do not store mixed solution. Administer consistently at same time each evening for optimal growth hormone rhythm.
Clinical Administration Guidelines
Injection Protocol
- •Subcutaneous injection per protocol
- •Rotate injection sites
- •Consistent daily timing
- •Follow protocol guidelines
Monitoring Schedule
- •Regular progress monitoring
- •Health parameter monitoring
- •Laboratory monitoring
- •Safety monitoring
Dosage Calculator
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Tesamorelin (Egrifta) is an FDA-approved prescription medication that should only be used under the supervision of a qualified healthcare provider. Treatment requires proper patient selection, monitoring, and management of potential side effects. Patients must be evaluated for contraindications including active malignancy and diabetic complications. Regular monitoring of glucose levels, IGF-1, and treatment response is essential for safe and effective use.